Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease

Abstract

Haemophilus influenzae serotype b (Hib) is an important cause of serious, invasive infections, particularly in young children. Since 1985, a series of vaccines composed of the type b capsular polysaccharide polyribosylribitol phosphate (PRP), followed by PRP conjugated to various proteins, have been licensed for use in the United States and worldwide. The conjugated vaccines offer increased immunogenicity and prolonged durability of immune protection compared to the plain PRP vaccine and increasingly are combined with other childhood vaccines for decreased cost and increased ease of vaccination. Hib vaccines have a very favorable safety profile, have been found to be either cost-saving or cost-effective by many public health agencies, and, in most countries, are initiated during early infancy as part of routine childhood immunization programs. As a result of widespread use of the vaccines, the incidence of Hib infections, and their associated morbidity and mortality, has fallen dramatically across the globe. Yet, many children remain unimmunized or underimmunized against Hib, particularly in limited-resource countries. Future efforts to further reduce the disease burden of Hib infections remain a high priority.

Keywords: PRP; meningitis; vaccine.

Figure 1.

Impact of Haemophilus influenzae type b (Hib) vaccines on incidence per 100 000 children <5 years old in the United States, 1980–2012 [29].

Figure 2.

Estimated annual incidence per 100 000 children aged <5 years of Haemophilus influenzae type b infection in the United States, 2000–2012 [29].